Aeon Biopharma Inc. closed a $20 million underwritten public offering on Jan. 7. The Irvine-based clinical-stage ...

Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 81.20% ...